ARHGEF9 disease

Michael Alber, Vera M. Kalscheuer, Elysa Marco, Elliott Sherr, Gaetan Lesca, Marianne Till, Gyri Gradek, Antje Wiesener, Christoph Korenke, Sandra Mercier, Felicitas Becker, Toshiyuki Yamamoto, Stephen W. Scherer, Christian R. Marshall, Susan Walker, Usha R. Dutta, Ashwin B. Dalal, Vanessa Suckow, Payman Jamali, Kimia Kahrizi & 2 others Hossein Najmabadi, Berge A. Minassian

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: We aimed to generate a review and description of the phenotypic and genotypic spectra of ARHGEF9 mutations. Methods: Patients with mutations or chromosomal disruptions affecting ARHGEF9 were identified through our clinics and review of the literature. Detailed medical history and examination findings were obtained via a standardized questionnaire, or if this was not possible by reviewing the published phenotypic features. Results: A total of 18 patients (including 5 females) were identified. Six had de novo, 5 had maternally inherited mutations, and 7 had chromosomal disruptions. All females had strongly skewed X-inactivation in favor of the abnormal X-chromosome. Symptoms presented in early childhood with delayed motor development alone or in combination with seizures. Intellectual disability was severe in most and moderate in patients with milder mutations. Males with severe intellectual disability had severe, often intractable, epilepsy and exhibited a particular facial dysmorphism. Patients with mutations in exon 9 affecting the protein's PH domain did not develop epilepsy. Conclusions: ARHGEF9 encodes a crucial neuronal synaptic protein; loss of function of which results in severe intellectual disability, epilepsy, and a particular facial dysmorphism. Loss of only the protein's PH domain function is associated with the absence of epilepsy.

Original languageEnglish (US)
Article numbere148
JournalNeurology: Genetics
Volume3
Issue number3
DOIs
StatePublished - Jul 1 2017

Fingerprint

Mutation
Intellectual Disability
Epilepsy
Absence Epilepsy
X Chromosome Inactivation
X Chromosome
Exons
Seizures
Proteins
Protein Domains
Pleckstrin Homology Domains

ASJC Scopus subject areas

  • Clinical Neurology
  • Genetics(clinical)

Cite this

Alber, M., Kalscheuer, V. M., Marco, E., Sherr, E., Lesca, G., Till, M., ... Minassian, B. A. (2017). ARHGEF9 disease. Neurology: Genetics, 3(3), [e148]. https://doi.org/10.1212/NXG.0000000000000148

ARHGEF9 disease. / Alber, Michael; Kalscheuer, Vera M.; Marco, Elysa; Sherr, Elliott; Lesca, Gaetan; Till, Marianne; Gradek, Gyri; Wiesener, Antje; Korenke, Christoph; Mercier, Sandra; Becker, Felicitas; Yamamoto, Toshiyuki; Scherer, Stephen W.; Marshall, Christian R.; Walker, Susan; Dutta, Usha R.; Dalal, Ashwin B.; Suckow, Vanessa; Jamali, Payman; Kahrizi, Kimia; Najmabadi, Hossein; Minassian, Berge A.

In: Neurology: Genetics, Vol. 3, No. 3, e148, 01.07.2017.

Research output: Contribution to journalArticle

Alber, M, Kalscheuer, VM, Marco, E, Sherr, E, Lesca, G, Till, M, Gradek, G, Wiesener, A, Korenke, C, Mercier, S, Becker, F, Yamamoto, T, Scherer, SW, Marshall, CR, Walker, S, Dutta, UR, Dalal, AB, Suckow, V, Jamali, P, Kahrizi, K, Najmabadi, H & Minassian, BA 2017, 'ARHGEF9 disease', Neurology: Genetics, vol. 3, no. 3, e148. https://doi.org/10.1212/NXG.0000000000000148
Alber M, Kalscheuer VM, Marco E, Sherr E, Lesca G, Till M et al. ARHGEF9 disease. Neurology: Genetics. 2017 Jul 1;3(3). e148. https://doi.org/10.1212/NXG.0000000000000148
Alber, Michael ; Kalscheuer, Vera M. ; Marco, Elysa ; Sherr, Elliott ; Lesca, Gaetan ; Till, Marianne ; Gradek, Gyri ; Wiesener, Antje ; Korenke, Christoph ; Mercier, Sandra ; Becker, Felicitas ; Yamamoto, Toshiyuki ; Scherer, Stephen W. ; Marshall, Christian R. ; Walker, Susan ; Dutta, Usha R. ; Dalal, Ashwin B. ; Suckow, Vanessa ; Jamali, Payman ; Kahrizi, Kimia ; Najmabadi, Hossein ; Minassian, Berge A. / ARHGEF9 disease. In: Neurology: Genetics. 2017 ; Vol. 3, No. 3.
@article{aeb321a1e7854dd09214e8878313111e,
title = "ARHGEF9 disease",
abstract = "Objective: We aimed to generate a review and description of the phenotypic and genotypic spectra of ARHGEF9 mutations. Methods: Patients with mutations or chromosomal disruptions affecting ARHGEF9 were identified through our clinics and review of the literature. Detailed medical history and examination findings were obtained via a standardized questionnaire, or if this was not possible by reviewing the published phenotypic features. Results: A total of 18 patients (including 5 females) were identified. Six had de novo, 5 had maternally inherited mutations, and 7 had chromosomal disruptions. All females had strongly skewed X-inactivation in favor of the abnormal X-chromosome. Symptoms presented in early childhood with delayed motor development alone or in combination with seizures. Intellectual disability was severe in most and moderate in patients with milder mutations. Males with severe intellectual disability had severe, often intractable, epilepsy and exhibited a particular facial dysmorphism. Patients with mutations in exon 9 affecting the protein's PH domain did not develop epilepsy. Conclusions: ARHGEF9 encodes a crucial neuronal synaptic protein; loss of function of which results in severe intellectual disability, epilepsy, and a particular facial dysmorphism. Loss of only the protein's PH domain function is associated with the absence of epilepsy.",
author = "Michael Alber and Kalscheuer, {Vera M.} and Elysa Marco and Elliott Sherr and Gaetan Lesca and Marianne Till and Gyri Gradek and Antje Wiesener and Christoph Korenke and Sandra Mercier and Felicitas Becker and Toshiyuki Yamamoto and Scherer, {Stephen W.} and Marshall, {Christian R.} and Susan Walker and Dutta, {Usha R.} and Dalal, {Ashwin B.} and Vanessa Suckow and Payman Jamali and Kimia Kahrizi and Hossein Najmabadi and Minassian, {Berge A.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1212/NXG.0000000000000148",
language = "English (US)",
volume = "3",
journal = "Neurology: Genetics",
issn = "2376-7839",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - ARHGEF9 disease

AU - Alber, Michael

AU - Kalscheuer, Vera M.

AU - Marco, Elysa

AU - Sherr, Elliott

AU - Lesca, Gaetan

AU - Till, Marianne

AU - Gradek, Gyri

AU - Wiesener, Antje

AU - Korenke, Christoph

AU - Mercier, Sandra

AU - Becker, Felicitas

AU - Yamamoto, Toshiyuki

AU - Scherer, Stephen W.

AU - Marshall, Christian R.

AU - Walker, Susan

AU - Dutta, Usha R.

AU - Dalal, Ashwin B.

AU - Suckow, Vanessa

AU - Jamali, Payman

AU - Kahrizi, Kimia

AU - Najmabadi, Hossein

AU - Minassian, Berge A.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Objective: We aimed to generate a review and description of the phenotypic and genotypic spectra of ARHGEF9 mutations. Methods: Patients with mutations or chromosomal disruptions affecting ARHGEF9 were identified through our clinics and review of the literature. Detailed medical history and examination findings were obtained via a standardized questionnaire, or if this was not possible by reviewing the published phenotypic features. Results: A total of 18 patients (including 5 females) were identified. Six had de novo, 5 had maternally inherited mutations, and 7 had chromosomal disruptions. All females had strongly skewed X-inactivation in favor of the abnormal X-chromosome. Symptoms presented in early childhood with delayed motor development alone or in combination with seizures. Intellectual disability was severe in most and moderate in patients with milder mutations. Males with severe intellectual disability had severe, often intractable, epilepsy and exhibited a particular facial dysmorphism. Patients with mutations in exon 9 affecting the protein's PH domain did not develop epilepsy. Conclusions: ARHGEF9 encodes a crucial neuronal synaptic protein; loss of function of which results in severe intellectual disability, epilepsy, and a particular facial dysmorphism. Loss of only the protein's PH domain function is associated with the absence of epilepsy.

AB - Objective: We aimed to generate a review and description of the phenotypic and genotypic spectra of ARHGEF9 mutations. Methods: Patients with mutations or chromosomal disruptions affecting ARHGEF9 were identified through our clinics and review of the literature. Detailed medical history and examination findings were obtained via a standardized questionnaire, or if this was not possible by reviewing the published phenotypic features. Results: A total of 18 patients (including 5 females) were identified. Six had de novo, 5 had maternally inherited mutations, and 7 had chromosomal disruptions. All females had strongly skewed X-inactivation in favor of the abnormal X-chromosome. Symptoms presented in early childhood with delayed motor development alone or in combination with seizures. Intellectual disability was severe in most and moderate in patients with milder mutations. Males with severe intellectual disability had severe, often intractable, epilepsy and exhibited a particular facial dysmorphism. Patients with mutations in exon 9 affecting the protein's PH domain did not develop epilepsy. Conclusions: ARHGEF9 encodes a crucial neuronal synaptic protein; loss of function of which results in severe intellectual disability, epilepsy, and a particular facial dysmorphism. Loss of only the protein's PH domain function is associated with the absence of epilepsy.

UR - http://www.scopus.com/inward/record.url?scp=85046892178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046892178&partnerID=8YFLogxK

U2 - 10.1212/NXG.0000000000000148

DO - 10.1212/NXG.0000000000000148

M3 - Article

VL - 3

JO - Neurology: Genetics

JF - Neurology: Genetics

SN - 2376-7839

IS - 3

M1 - e148

ER -